
Sight Sciences (SGHT) Stock Forecast & Price Target
Sight Sciences (SGHT) Analyst Ratings
Bulls say
Sight Sciences Inc. is positively positioned for growth, largely due to its Surgical Glaucoma segment, which is expected to sustain its expansion in alignment with the overall minimally invasive glaucoma surgery (MIGS) market. The company anticipates stronger revenue growth driven by faster market share gains in MIGS and quicker adoption of its TearCare System, while also making progress toward achieving profitability. Furthermore, revenue projections for 2025 and 2026 are forecasted at $75 million and $82 million, respectively, alongside improved earnings per share expectations, indicating a strengthening financial outlook.
Bears say
Sight Sciences Inc. maintains a revenue guidance of $72-76 million for 2025, with expectations of a mid-single-digit percentage decline in the Surgical Glaucoma segment for the third quarter of 2025. The company faces significant risks, including escalating competition in minimally invasive glaucoma surgery (MIGS), delayed insurance coverage progress for its TearCare product, and continued high quarterly cash burn rates. Additionally, management has revised its adjusted operating expenditure forecast downward to $95-99 million from an earlier estimate of $101-105 million, although this reduction reflects anticipated savings from a restructuring initiative.
This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.
Sight Sciences (SGHT) Analyst Forecast & Price Prediction
Start investing in Sight Sciences (SGHT)
Order type
Buy in
Order amount
Est. shares
0 shares